<DOC>
	<DOCNO>NCT03053739</DOCNO>
	<brief_summary>The study carry 50 consecutive consenting patient systemic sclerosis PAH recruit outpatient department internal medicine rheumatology clinic PGIMER , Chandigarh , India It single centre double blind randomise control trial evaluate effect upfront dual therapy ( sildenafil bosentan ) v monotherapy ( sildenafil ) Participants randomise 1:1 ratio one treatment arm . Placebo PDE-5 inhibitor 20 mg BD 60 mg patient tolerate drug well one study arm PDE-5 inhibitor plus ER antagonist 62.5 max 125 study group</brief_summary>
	<brief_title>To Compare Efficacy Combination Therapy v Monotherapy Pulmonary Arterial Hypertension Systemic Sclerosis</brief_title>
	<detailed_description>All patient fulfil SSc classification criterion American College Rheumatology study period screen presence PAH . Diagnosed case PAH base CD echo PAP &gt; 35mmHg base echocardiography enrol study.Baseline NYHA functional class 6 min walk distance meter assess . Heamogram LFT measure Patients assess two week side effects/safety issue . 6MWT NYHA functional class reassess 3 month 6 months.2D echo do 6 month measure mPAP RandomizationAll eligible patient randomize 1:1 ratio block ten two arm . Randomization stratify base severity PAH . The drug label A B randomly another staff member , involve decide treatment study subject . The randomization sequence generate use computer random number generator . Blinding ensure match placebo ERA one group label one treatment arm ' A ' treatment arm ' B ' . Allocation concealment ensure mean enclose randomization sequence seal opaque envelope . Sealed opaque envelope contain Code ' A ' Code ' B ' . Intervention-The study consist two treatment arm . The study drug mainly Bosentan Placebo pack match tablet dosage 62.5 mg. One treatment arm contain Sildenafil Placebo treatment arm contain Sildenafil Bosentan . Treatment initiate 20 mg twice day Sildena-fil combination placebo day one treatment arm Bosentan 62.5 mg day treatment arm .Dose Sildenafil increase 20 mg thrice day four week Bosentan 62.5 mg twice day . Placebo also provide twice day.This continue till end study period.. Dose adjustment case adverse event make depend severity adverse event . Statistical analysis- Intention treat analysis carry primary secondary outcome . For continuous outcome , unpaired t-test dichotomous outcome chi-squares test Yate 's correction use . P &lt; 0.05 consider significant</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Male female patient age 18 year Patients systemic sclerosis PAH diagnose PAP &gt; 35mmHg NYHA functional class II , III , IV SSc disease duration &gt; 1years Forced vital capacity &lt; 60 % predict Renal insufficiency Left heart disease relevant cardiac condition Pregnant breastfeed female Patients PAH specific therapy Liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Systemic sclerosis , Associated Pulmonary Arterial Hypertension</keyword>
</DOC>